A study on ADI clinical trials has demonstrated that ADI can prolong progression-free survival in patients with ASS1-deficient mesothelioma (3.2 vs. 2.0 months), and that the overall patient survival in the ADI and control group is 15.7 and 12.3 months, respectively [40]. This evidence concerns the gene ASS1 and mesothelioma.